Skip to main content
OpenTrials
Completed

NCT Number: NCT03213743

Expression Profiling of microRNA Following Administration of Dexmedetomidine

The purpose of the study is to find out the differential expression profiling of microRNA before and after adiministration of dexmedetomidine in patients undergoing procedures, and then investigators will do some in vitro studies to validate the functions of the microRNA.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Coronary Disease Cardiovascular Diseases Heart Diseases Myocardial Ischemia Vascular Diseases

Age range

40 year–70 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

Jinqiao Qian

Kunming, Yunnan, 650032, China

About this study

Background and objective: The use of dexmedetomidine may have benefits on the clinical outcomes of cardiac surgery. MicroRNAs are non-coding RNA sequences that act as regulators of gene expression. Investigators conduct a study to determine the role of microRNAs in cardioprotection mediated by dexmedetomidine.

Methods: In this study 3 patients were selected. The blood sample were taken before administration of dexmedetomidine.Investigators infused loading dose of dexmedetomidine for 10 minutes and maintaining dese of dexmedetomidine for 20 minutes.Thirty minutes after the administration, another blood samples were taken and stored in the liquid nitrogen and both the samples were marked. Those sample were analyzed for differentially expressed microRNA with Exiqon miRNA Array.

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • The patients without arrithmia will undergo procedure.

Exclusion criteria

  • The patients have bradycardia (hear rate is less than 60 beats per minute) or conduction block.

Treatment and study plan

Dexmedetomidine Injection

Drug

Investigators gave the patients loading dose of dexmedetomidine for 10 minutes and maintaining dose of dexmedetomidine for 20 minutes. Investigators took blood samples before and after the administration of dexmedetomidine.

Other names: Dex group

Primary outcomes

  1. microRNA differential expression

    Time frame: 30 minutes

    microRNA differential expression exerts cardioprotection effect on patients undergoing procedures.

Sponsors and collaborators

Lead sponsor

First Affiliated Hospital of Kunming Medical University

Other

Registry information

Official study title

Expression Profiling of microRNA Following Administration of Dexmedetomidine in Patients Undergoing Procedures

Important dates

Study start
2017
Primary completion
2017
Study completion
2017
First posted
Jul 11, 2017
Registry last updated
Jul 11, 2017

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.